Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3819339 | 0.98 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2LMNAUSP2CYP1A2 | |
| SCHEMBL5042569 | 0.98 | USP2 (0.36) | ALDH1A1SMN1; SMN2LMNAUSP2CYP1A2 | |
| Tetrabuthylammonium SCHEMBL5971657 | 0.84 | SLC22A1 (0.35) | ALDH1A1SMN1; SMN2LMNAUSP2CYP1A2 | |
| SCHEMBL14883391 | 0.81 | ALDH1A1 (0.32) | ALDH1A1LMNATSHR | |
| SCHEMBL13649534 | 0.81 | ALDH1A1 (0.32) | ALDH1A1LMNATSHR | |
| SCHEMBL15174049 | 0.81 | USP2 (0.45) | ALDH1A1SMN1; SMN2LMNAUSP2CYP1A2 | |
| SCHEMBL440062 | 0.81 | ALDH1A1 (0.32) | ALDH1A1LMNATSHR | |
| SCHEMBL3400975 | 0.81 | LMNA (0.41) | ALDH1A1SMN1; SMN2LMNAUSP2CYP1A2 | |
| SCHEMBL7080628 | 0.80 | USP2 (0.37) | ALDH1A1SMN1; SMN2LMNAUSP2CYP1A2 | |
| SCHEMBL5046792 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 408 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118726654-A | Primer group and kit for detecting rotavirus and application of primer group and kit | 科兴（大连）疫苗技术有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-118341476-A | Porous Raney nickel base alloy catalyst, preparation method and application thereof in low-temperature hydrogenation reaction | 浙江工业大学 | 2024-07-16 | — | — | CN | claimed |
| WO-2019011879-A1 | THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME | HENNING RAINER (CH) | 2019-01-17 | — | — | WO | claimed |
| US-8114909-B2 | Utilizing extended release forms with reduced rates of systemic clearance; eliminating significant side effects | XENOPORT, INC. (US) | 2012-02-14 | — | — | US | claimed |
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | claimed |
| US-20110294881-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING alpha2delta SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | EDUSA PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | claimed |
| EP-2334324-A2 | BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY | Fibrex Medical Research & Development GmbH (AT) | 2011-06-22 | — | — | EP | claimed |
| EP-2328925-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-06-08 | — | — | EP | claimed |
| EP-2274328-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-01-19 | — | — | EP | claimed |
| JP-4499362-B2 | — | — | 2010-07-07 | — | — | JP | claimed |
| US-20040077543-A1 | Treatment using neublastin polypeptides | BIOGEN IDEC MA INC. | 2004-04-22 | — | — | US | claimed |
| EP-1395279-A2 | USE OF NEUBLASTIN POLYPEPTIDES FOR TREATING NEUROPATHIC PAIN | BIOGEN, INC. (US) | 2004-03-10 | — | — | EP | claimed |
| WO-2003104184-A1 | METHODS FOR SYNTHESIS OF ACYLOXYALKYL DERIVATIVES OF GABA ANALOGS | XENOPORT, INC. (US) | 2003-12-18 | — | — | WO | claimed |
| WO-2002078730-A2 | USE OF NEUBLASTIN POLYPEPTIDES FOR TREATING NEUROPATHIC PAIN | BIOGEN, INC. (US) | 2002-10-10 | — | — | WO | claimed |
| WO-2000032167-A9 | A POLYSOME | SDG INC (US) | 2001-12-13 | — | — | WO | claimed |
| WO-2000032167-A1 | A POLYSOME | SDG, INC. (US) | 2000-06-08 | — | — | WO | claimed |
| US-5149870-A | Process for the production of 1-(aminomethyl)cyclohexane acetic acid | LONZA LTD. (CH) | 1992-09-22 | — | — | US | claimed |
| US-5136091-A | Alcoholysis, hydrolysis, transesterification, and hydrogenatio hydrogenation; acid & basic catalysts; anticonvulsants | LONZA LTD. (CH) | 1992-08-04 | — | — | US | claimed |
| US-5095148-A | PROCESS FOR THE PRODUCTION OF 1-(AMINOMETHYL)CYCLOHEXANE ACETIC ACID | LONZA LTD. (CH) | 1992-03-10 | — | — | US | claimed |
| EP-0358092-B1 | 2-AZA-4-(ALKOXYCARBONYL)SPIRO-(4,5)DECAN-3-ONE | LONZA A.G. (CH) | 1991-12-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294881-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING alpha2delta SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | GABRB2, GABRB3, GABRB1 | ALDH1A1 1342/4885SMN1; SMN2 1070/4885LMNA 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.